Paolo Persichetti

Dr. Paolo Persichetti


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Archives of Plastic Surgery
Verified
Journal Article
Open access
PDF file
APAurelia Trisliana Perdanasari
Aurelia Trisliana Perdanasari
DLDavide Lazzeri
Davide Lazzeri
WSWeijie Su
Weijie Su
WXWenjing Xi
Wenjing Xi
ZZZhang Zheng
Zhang Zheng
PPPaolo Persichetti
Paolo Persichetti
Keloid scars are often considered aesthetically unattractive and frustrating problems that occur following injuries. They cause functional and cosmetic deformities, displeasure, itching, pain, and psychological stress and possibly affect joint movement. The combination of these factors ultimately results in a compromised quality of life and diminished functional performance. Various methods have been implemented to improve keloid scars using both surgical and non-surgical approaches. However, it has proven to be a challenge to identify a universal treatment that can deliver optimal results for all types of scars. Through a PubMed search, we explored most of the literature that is available about the intralesional injection treatment of hypertrophic scars and keloids and highlights both current (corticosteroid, 5-fluorouracil, bleomycin, interferon, cryotherapy and verapamil) and future treatments (interleukin-10 and botulinum toxin type A). The reference lists of retrieved articles were also analysed. Information was gathered about the mechanism of each injection treatment, its benefits and associated adverse reactions, and possible strategies to address adverse reactions to provide reliable guidelines for determining the optimal treatment for particular types of keloid scars. This article will benefit practitioners by outlining evidence-based treatment strategies using intralesional injections for patients with hypertrophic scars and keloids.

4 January 2007 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
PPPaolo Persichetti
Paolo Persichetti
PSPierfranco Simone
Pierfranco Simone
MLMarika Langella
Marika Langella
GMGiovanni Francesco Marangi
Giovanni Francesco Marangi
CCCarlo Carusi
Carlo Carusi

1 April 2001 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
PPPaolo Persichetti
Paolo Persichetti
MBMarco Berloco
Marco Berloco
RCRenato Muccioli M.S. Casadei
Renato Muccioli M.S. Casadei
GMGiovanni F. M.S. Marangi
Giovanni F. M.S. Marangi
FLFilippo Di Lella
Filippo Di Lella
ANAndrea M. M.S. Nobili
Andrea M. M.S. Nobili
Gynecomastia is a benign enlargement of the male breast due to a physiological or pathological factor that interferes with the balance between estrogens and androgens in the serum. Gynecomastia itself requires no treatment unless the persistent enlargement of the male breast is a source of embarrassment and/or distress for the adolescent or adult man. The indications for the surgical treatment of gynecomastia are founded on two main objectives: (1) the restoration of male chest shape and (2) diagnostic evaluation of suspected breast lesions. The diagnostic evaluation begins with an adequate history and a thorough breast examination helped by laboratory tests and instrumental research. Several approaches for surgical treatment have been described in the literature. Some problems arise in patients who have significant enlargement and ptosis of the breast that will require skin reduction and in some patients requiring nipple-areola complex reduction. The authors believe that the complete circumareolar technique with purse-string suture creates the best aesthetic results, with fewer complications, in patients with moderate and severe ptotic glandular breast enlargements that have skin redundancy combined with areolar enlargement. From 1995 through 1999, a total of 10 male patients with moderate to severe gynecomastia were treated surgically using a complete circumareolar approach. All patients achieved a good aesthetic contour of the chest. Only two patients required a revision of the circumareolar scar to correct postoperative enlargement. (Plast. Reconstr. Surg. 107: 948, 2001.)

1 August 2007 in Annals of Plastic Surgery
Verified
Journal Article
Closed access
PPPaolo Persichetti
Paolo Persichetti
ACAnnalisa Cogliandro
Annalisa Cogliandro
GMGiovanni Francesco Marangi
Giovanni Francesco Marangi
PSPierfranco Simone
Pierfranco Simone
VRValter Ripetti
Valter Ripetti
RCRoberto Coppola
Roberto Coppola

23 December 2003 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
VEV Esposito
V Esposito
Alfonso BaldiAlfonso Baldi
Alfonso Baldi
GTG Tonini
G Tonini
BVBruno Vincenzi
Bruno Vincenzi
MSMario SANTINI
Mario SANTINI
AGA M Groeger
A M Groeger
Background/Aims: Abnormalities of the proteins involved in cell cycle checkpoints are extremely common among almost all neoplasms. This study aimed to investigate the expression of four components of the cell cycle machinery—p21, p16, p53, and proliferating cell nuclear antigen (PCNA)—in non-small cell lung cancer (NSCLC). Methods: The expression of p21, p16, p53, and PCNA was examined in 68 well characterised NSCLC specimens using immunohistochemistry. The coregulation of these proteins and their influence on survival were analysed using both univariate and multivariate analyses. Results: By univariate analysis, the expression of all the proteins examined, except for PCNA, was significantly correlated with survival. In multivariate analysis, the only immunohistochemical parameter able to influence overall survival was p16, confirming the hypothesis that the RB–p16 tumour suppressor pathway is inactivated in most lung cancer samples. Finally, the group of patients with NSCLC who were negative for both p21 and p16 had a significantly shorter overall survival. Conclusions: These results suggest that loss of control of cell cycle checkpoints is a common occurrence in lung cancers, and support the idea that functional cooperation between different cell cycle inhibitor proteins constitutes another level of regulation in cell growth control and tumour suppression.

5 December 2020 in Biology
Verified
Journal Article
Open access
PDF file
CCClaudio Conforti
Claudio Conforti
CDCaterina Dianzani
Caterina Dianzani
MAMarina Agozzino
Marina Agozzino
Roberta GiuffridaRoberta Giuffrida
Roberta Giuffrida
GMGiovanni Francesco Marangi
Giovanni Francesco Marangi
NNNicoleta Neagu
Nicoleta Neagu
There have been increasing reports of skin manifestations in COVID-19 patients. We conducted a systematic review and included manuscripts describing patients with positive RT-PCR coronavirus testing from nasopharyngeal swabs who also developed cutaneous manifestations. A total of 655 patients were selected, with different types of skin rashes: Erythematous maculopapular (n = 250), vascular (n = 146), vesicular (n = 99), urticarial (n = 98), erythema multiforme/generalized pustular figurate erythema/Stevens-Johnson syndrome (n = 22), ocular/periocular (n = 14), polymorphic pattern (n = 9), generalized pruritus (n = 8), Kawasaki disease (n = 5), atypical erythema nodosum (n = 3), and atypical Sweet syndrome (n = 1). Chilblain-like lesions were more frequent in the younger population and were linked to a milder disease course, while fixed livedo racemosa and retiform purpura appeared in older patients and seemed to predict a more severe prognosis. For vesicular rashes, PCR determined the presence of herpesviruses in the vesicle fluid, which raised the possibility of herpesvirus co-infections. The erythema-multiforme-like pattern, generalized pustular figurate erythema and Stevens-Johnson syndrome were most frequently linked to hydroxychloroquine intake. A positive PCR determination of SARS-COV-2 from conjunctival swabs suggest that eye discharge can also be contagious. These cutaneous manifestations may aid in identifying otherwise asymptomatic COVID-19 carriers in some cases or predict a more severe evolution in others.